

The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked to the Presence of Long COVID Symptoms

Short Title: Antibody Breadth and Long COVID

AUTHORS

Amanda M. Buck^{1*}, Amelia N. Deitchman^{6*}, Saki Takahashi², Scott Lu³, Sarah A. Goldberg³, Rebecca Hoh², Meghann C. Williams², Marian Kerbleski², Tyler-Marie Deveau¹, Sadie E. Munter¹, James Lombardo², Terri Wrin⁴, Christos J. Petropoulos⁴, Matthew S. Durstenfeld⁵, Priscilla Y. Hsue⁵, J. Daniel Kelly³, Bryan Greenhouse², Jeffrey N. Martin³, Steven G. Deeks², Michael J. Peluso^{2**}, Timothy J. Henrich^{1**}

¹ Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United States

² Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA, United States

³ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, United States

⁴ Monogram Biosciences, South San Francisco, CA, United States

⁵ Division of Cardiology, University of California San Francisco, San Francisco, CA, United States

⁶ Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, United States

*contributed equally, ^co-corresponding author

Corresponding Authors:

Michael J. Peluso

michael.peluso@ucsf.edu

Division of HIV, Infectious Diseases, and Global Medicine

University of California San Francisco

1001 Potrero Ave

San Francisco, CA 94110

Timothy J. Henrich

timothy.henrich@ucsf.edu

Division of Experimental Medicine

University of California San Francisco

1001 Potrero Ave

San Francisco, CA 94110

Summary: SARS-CoV-2-specific antibody neutralization of Omicron BA.5 variant approximately 4 months following acute infection with wild-type virus prior to vaccination was independently and significantly associated with greater odds of distinct Long COVID phenotypes.

46 **ABSTRACT**

47 **Background:** The associations between longitudinal dynamics and the breadth of SARS-CoV-2
48 neutralizing antibody response with various Long COVID (LC) phenotypes prior to vaccination are not
49 known. The capacity of antibodies to cross neutralize a variety of viral variants may be associated with
50 ongoing pathology and persistent symptoms.

51 **Methods:** We measured longitudinal neutralizing and cross-neutralizing antibody responses to pre- and
52 post-SARS-CoV-2 Omicron variants in participants infected during the early waves of the COVID-19
53 pandemic, prior to wide-spread rollout of SARS-CoV-2 vaccines. Cross sectional regression models
54 adjusted for various clinical covariates and longitudinal mixed effects models were used to determine
55 the impact of the breadth and rate of decay of neutralizing responses on the development of Long
56 COVID symptoms in general, as well as LC phenotypes.

57 **Results:** We identified several novel relationships between SARS-CoV-2 antibody neutralization and
58 the presence of LC symptoms. Specifically, we show that, although neutralizing antibody responses to
59 the original, infecting strain of SARS-CoV-2 were not associated with LC in cross-sectional analyses,
60 cross-neutralization ID50 levels to the Omicron BA.5 variant approximately 4 months following acute
61 infection was independently and significantly associated with greater odds of LC and with persistent
62 gastrointestinal and neurological symptoms. Longitudinal modeling demonstrated significant
63 associations in the overall levels and rates of decay of neutralization capacity with LC phenotypes. A
64 higher proportion of participants had antibodies capable of neutralizing Omicron BA.5 compared with
65 BA.1 or XBB.1.5 variants.

66 **Conclusions:** Our findings suggest that relationships between various immune responses and LC are
67 likely complex but may involve the breadth of antibody neutralization responses.

68 **Keywords:** COVID-19, SARS-CoV-2; Neutralizing Antibodies; Long COVID; Post-Acute Sequelae of
69 SARS-CoV-2 infection (PASC)

70 INTRODUCTION

71 Many individuals experience post-acute sequelae of SARS-CoV-2 infection (PASC), which can affect
72 quality of life and return to health [1-3]. The etiologic drivers of Long COVID (LC), a form of PASC
73 defined by ongoing, often debilitating, symptoms, are poorly understood and likely involve multiple
74 mechanisms [2, 4, 5]. Proposed mechanisms include aberrant autoreactive immune responses,
75 microvascular dysregulation, and reactivation of latent human herpesviruses which may lead to the
76 systemic inflammatory responses now identified in individuals with Long COVID compared to those
77 who fully recovered [6-11]. Furthermore, there is growing evidence that SARS-CoV-2 subgenomic RNA
78 and proteins are present in the tissues of at least a subset of immunocompetent individuals with LC [12-
79 14]. Although those with persistent symptoms tend to have higher levels of SARS-CoV-2 Spike-specific
80 antibody levels [10, 15-18], we and others have previously demonstrated that LC is associated with
81 adaptive immune dysregulation and exhaustion [15, 18].

82 SARS-CoV-2 infection leads to rapid development of robust antibody responses, although neutralizing
83 capacity wanes more quickly than total Spike IgG levels over time [17, 19-21]. A higher initial viral
84 burden or persistence of viral antigens may lead to observed dysregulated immune phenotypes and
85 higher antibody levels. However, there is a paucity of information regarding the associations between
86 longitudinal dynamics or the breadth of the neutralizing antibody response with various LC phenotypes
87 with some data showing that weaker antibody responses over time being associated with LC [22].

88 Recent pre-print data suggests that an expanded antibody response against the prior OC43 endemic
89 coronavirus may be associated with Long COVID [23]. This suggests that the breadth of the response
90 to initial infection may play an important role in the development of LC. Given that the rapid emergence
91 of Omicron variants that evade neutralization result from infection from older SARS-CoV-2 strains (e.g.,
92 ancestral SARS-CoV-2, Alpha and Delta variants) as well as to COVID-19 vaccines [24, 25], there is
93 strong interest in determining the relationship between the breadth and durability of the initial antibody
94 responses and the presence of Long COVID symptoms. The rapid emergence of novel variants and

95 increased incidence of reinfection also necessitates studies of longitudinal antibody responses following
96 COVID-19 [26].

97 Here, we measured longitudinal neutralizing antibody responses to pre-Omicron strains and to
98 subsequent Omicron variants in participants infected during the early waves of the COVID-19
99 pandemic, prior to their receiving SARS-CoV-2 vaccines. Cross sectional regression models adjusted
100 for various clinical covariates and longitudinal mixed effects models were used to determine the impact
101 of the breadth and rate of decay of neutralizing responses on the development of Long COVID
102 symptoms in general, as well as distinct Long COVID symptom phenotypes.

103

104 **METHODS**

105 **Clinical Cohort and Sample Collection.** Participants were enrolled in the University of California, San
106 Francisco (UCSF)-based Long-term Impact of Infection with Novel Coronavirus (LIINC) COVID-19
107 study (NCT04362150). The cohort design and procedures have been described in detail elsewhere [4].
108 Briefly, at each visit participants complete an interviewer-administered questionnaire querying the
109 presence in the preceding 2 days of symptoms that are new since COVID-19 or worsened from pre-
110 COVID baseline, prior to the collection of peripheral blood. This analysis included longitudinal
111 measurements from 184 participants, including plasma samples collected between 1 and 4 months
112 after initial symptom onset. All samples were collected prior to the participant having received any
113 SARS-CoV-2 vaccination and a large majority were collected during the original SARS-CoV-2 wave
114 (timing of sample collections here- maybe first and last date of collection), all prior to Omicron variant
115 emergence. Phenotypic clusters were based on 32 participant-reported symptoms as previously
116 described [4].

117 **PhenoSense SARS CoV-2 nAb Assay.** The measurement of nAb activity using the PhenoSense
118 SARS CoV-2 nAb Assay (Monogram Biosciences, South San Francisco, CA) was performed by

119 generating HIV-1 pseudovirions that express the SARS CoV-2 Spike protein as previously described
120 [20, 27-29]. The pseudovirus is prepared by co-transfecting HEK293 producer cells with an HIV-1
121 genomic vector that contains a firefly luciferase reporter gene together with a SARS CoV-2 Spike
122 protein expression vector. Neutralizing antibody activity is measured by assessing the inhibition of
123 luciferase activity in HEK293 target cells expressing the ACE2 receptor and TMPRSS2 protease
124 following pre-incubation of the pseudovirions with serial dilutions of the serum specimen. ID50 values
125 was generated for the original SARS-CoV-2 Spike protein as well as the following variants: Alpha
126 (B.1.1.7), D614G mutant, Delta (B.1.617.2), Omicron BA.1 (B.1.1.529), Omicron BA.5 (B.1.1.529). A
127 subset of samples stratified by negative or ID50s to the BA.5 strain were performed in an expanded
128 pool consisting of pseudoviruses incorporating spike proteins from BA.2, BA.4.6, XBB.1.5 and BQ.1.1.

129 **Statistical analyses.** Antibody data were generated blinded to participant information. Comparisons of
130 ID50 values across comparator groups incorporated non-parametric Mann-Whitney or Freidman tests
131 with Dunn correction for multiple comparisons using Prism v. 8 (GraphPad Software) and SPSS v. 29
132 (IBM). Adjusted P values reported in analyses involving multiple comparisons. For tabular data, two-
133 tailed Fisher's exact testing was performed on categorical data and two-tailed, non-parametric Mann-
134 Whitney testing was performed on continuous variables (SPSS v. 29). Spearman Rank Correlation
135 analysis was used to compare T cell, antibody and soluble markers of inflammation (Prism v. 8). For
136 longitudinal analyses, linear mixed effects modeling was performed for neutralizing antibody ID50 (log
137 transformed) in R (version 4.0.2) using lme4 package (version 1.1) with time and individual factors
138 (e.g., age, sex, COVID-19 hospitalization, prior history of diabetes, prior autoimmune disease, body
139 mass index >30, Long COVID symptoms) as predictors, and random effects based on participant.
140 Spearman's correlation was performed in R to test for relationships between variant neutralizing
141 antibody ID50 across all time points. Logistic regression models were performed on cross sectional
142 data including the constant to identify independent associations between model factors and Long
143 COVID outcomes using SPSS v. 29. Models included various demographic variables as well as either

144 Log-transformed ID50 values or binary categorical indicators of ID50 values above a specific threshold
145 as determined by sensitivity analyses.

146 **Study approval.** All participants provided signed written informed consent prior to participation. The
147 UCSF IRB approved the study.

148

149 **RESULTS**

150 **Clinical cohort and participant demographics.** To evaluate neutralizing responses in participants
151 with prior COVID-19 and to assess relationships between these responses and the presence of Long
152 COVID symptoms, we analyzed plasma samples collected from 184 participants with and without Long
153 COVID symptoms across 384 timepoints for up to 4 months following acute infection. Participants had a
154 median of 2 sample time points across all visits (ranging from 1 to 4). In general, participant visits
155 occurred approximately 1 month, 2 months or 4 months following nucleic acid-confirmed SARS-CoV-2
156 infection. All specimens and symptom reports were timed from the day of initial COVID-19 symptom
157 onset.

158 All participants were initially infected prior to emergence of the Delta strain (last date of infection was in
159 March of 2021) and all but 7 samples across all time points were collected prior to the end of February
160 2021 (the time of vaccine availability to the general public in the United States). Long COVID was
161 defined broadly as the presence of any symptom new or worsened since acute SARS-CoV-2 infection
162 not clearly attributable to another cause. **Table 1** shows the clinical and demographic factors of
163 participants grouped by the presence or absence of any Long COVID symptom. The group with Long
164 COVID was enriched for women (58.4% vs 39.4%, $P < 0.05$), those who had been hospitalized during
165 acute COVID-19 (24.8% vs 19.7%, not significant), those with a history of pre-existing autoimmune
166 disease (mainly thyroiditis, 10.6% vs 1.4%, $P < 0.05$), persons self-reporting Latinx ethnicity (34.5% vs
167 19.7%, $P < 0.05$), and those with higher body mass index (27.7 vs 26.0 kg/m², $P < 0.05$) (**Table 1**).

168 **Breadth of antibody neutralization to the original infecting SARS-CoV-2 variant and subsequent**
169 **viral variants.** Using the PhenoSense assay (Monogram Biosciences), we measured the inhibitory
170 serum dilutions at which 50% neutralization occurred (ID50) using pseudoviruses expressing SARS-
171 CoV-2 Spike protein from the original strain (with which a majority of our participants were infected) and
172 the following subsequent variants: Alpha (B.1.1.7), D614G mutant, Delta (B.1.617.2), Omicron BA.1
173 (B.1.1.529), and Omicron BA.5 (B.1.1.529). Overall, neutralization levels were highly variable between
174 participants. Antibody neutralization responses were consistently highest to the original, infecting
175 SARS-CoV-2 strain along with the Alpha, Beta, and Delta variants, with levels declining between 1 and
176 4 months following acute infection (**Figure 1A-C**). Although very low levels of cross-neutralization were
177 observed with the Omicron BA.1 variant, a higher proportion of participants had antibodies able to
178 neutralize Omicron BA.5 up to four months following initial presentation (the last study time point).
179 Across all time points, 12.5% of neutralizing titers were below the level of assay positivity to the original
180 SARS-CoV-2 pseudovirus and 78.4% and 67.4% below the level of positivity for the BA.1 and BA.5
181 variant, respectively. Correlations of neutralization capacity to each SARS-CoV-2 variant are shown in
182 **Supplementary Figure 1.**

183 We tested a subset of 16 participants including samples chosen with either high or low Omicron BA.5
184 responses across all timepoints on an expanded panel of Omicron sub variants to better understand
185 the full breadth of cross-neutralization responses between ancestral and recent or current circulating
186 strains as shown in **Figure 1D**. The expanded neutralization panel included BA.4.6, BQ.1.1 and
187 XBB.1.5. Similar neutralization titers were observed between BA.5, BA.4.6, and BQ1.1, whereas
188 XBB.1.5 responses most closely resembled BA.1 responses, which were overall low or negative across
189 participants. BA.2 responses were more evenly distributed across a range of neutralization ID50s
190 compared to the other Omicron sub variants.

191 **Decay of variant-specific SARS-CoV-2 antibody neutralization by clinical phenotype.** Leveraging
192 mixed effects modeling approaches, we analyzed neutralizing responses over time by clinical and

193 demographic characteristics, including age, sex, hospitalization during acute infection, body mass index
194 (BMI), and a pre-existing history of diabetes mellitus for the most clinically relevant variants in our study
195 population (ancestral SARS-CoV-2, Delta and Omicron sub variants; **Figure 2**). Overall, antibody
196 neutralization ID50 decreased over time for all strains ($p < 0.01$) with the exception of the Omicron BA.1
197 variant, ($p = 0.16$) for which initial levels were substantially lower than to the other variants. When
198 stratifying by age greater than 50 years, we identified no difference in antibody neutralization to all
199 variants tested across all time points in the mixed effects models. In contrast, male sex was associated
200 with higher viral neutralization for original SARS-CoV-2, Delta, and Omicron BA.5 variants, but not for
201 Omicron BA.1, across all time points. These observed sex-based differences were similar between
202 original and Delta variants, each approximately 0.41 and 0.33 \log_{10} higher, respectively, observed in
203 males compared to females recovering from COVID-19.

204 For those hospitalized during acute infection, neutralization levels were significantly higher across all
205 strains with the exception of BA.1. The magnitude of the difference in responses for those hospitalized
206 versus not hospitalized was diminished with those strains with lower overall responses: 1.18 and 0.94
207 \log_{10} higher responses for the original virus and Delta variant versus 0.33 and 0.28 \log_{10} higher for
208 omicron BA.1 and BA.5 responses, respectively. Individuals with pre-existing diabetes also had
209 differential neutralization across variants, with higher initial levels and longitudinal levels over all time
210 points, and showing a more rapid decline over time compared to those without diabetes. The
211 magnitude of wild-type SARS-CoV-2 responses for those with a BMI > 30 was higher across all time
212 points for the original and delta viral strains (All $P < 0.001$) and declined more rapidly for the original
213 Delta and Omicron BA.5 variants (All $P > .012$; **Supplemental Figure 2**). In contrast, neutralization
214 ID50s from participants with a pre-existing history of diabetes mellitus were overall lower across all time
215 points for the original SARS-CoV-2 (All $P < 0.05$) and ID50s to the original strain and Delta variant
216 declined less rapidly ($P < 0.05$).

217 **Breadth of the neutralizing antibody responses is associated with increased odds of Long**
218 **COVID.** In order to determine whether neutralization capacity was related to Long COVID, we
219 performed logistic regression modeling with either the presence of any Long COVID symptom at a
220 given sample time point or with specific Long COVID symptom phenotype (neurocognitive,
221 cardiopulmonary, gastrointestinal, musculoskeletal and fatigue) at the three main collection time points:
222 1 month (N=69; median 33 days), 2 months (N=115; median 59 days) and 4 months (N=119; median
223 120 days) following acute infection. Data from only one time point per participant within each time
224 period was included to avoid oversampling of specific individuals. Specifically, the sample time closest
225 to 30 days within a 21-45 day window, 60 days within a 56-75 day window, and 120 days within a 100-
226 150 day window were included. Factors included in the first model (**Figure 3A**) included the neutralizing
227 antibody ID50 (continuous variable), prior hospitalization during acute COVID-19, female sex, and age
228 greater than 50 years of age. Overall, there were no significant differences between neutralization ID50
229 to any strain and the presence of Long COVID in general or any specific Long COVID phenotype at 1
230 and 2 months following acute infection (all $P > 0.05$). As shown in **Figure 3A**, the neutralization ID50 of
231 the ancestral SARS-CoV-2 (the infecting strain in this study population), as well as Alpha and Delta
232 variants, were not significantly associated with the presence of any Long COVID symptom or specific
233 Long COVID phenotype approximately 4 months after acute infection. However, cross-neutralization
234 ID50s to Omicron BA.5 were significantly and positively associated with neurocognitive and
235 gastrointestinal symptoms (*i.e.* higher odds of having symptoms within these phenotypes). There were
236 no significant associations between BA.5 neutralization ID50 and fatigue and cardiopulmonary
237 symptoms or as shown in **Supplementary Figure 3**). Regression analyses including ID50s to both
238 wild-type SARS-CoV-2 and Omicron BA.3 were also performed as in **Supplementary Figure 4A**.
239 Including ID50s to both wild type and BA.5 strains led to similar results, with cross-neutralization to
240 Omicron BA.5 being significantly associated with having any Long COVID symptom and neurocognitive
241 symptoms, whereas ancestral SARS-CoV-2 ID50 were not significantly associated with Long COVID or
242 any symptoms cluster.

243 Female sex was positively and significantly associated with an increased odds of Long COVID in
244 models including both the original infecting virus and cross-neutralization to the Omicron BA.5 variant.
245 Hospitalization for acute COVID-19 was only significantly associated with Long COVID in the model
246 incorporating the original SARS-CoV-2 strain pseudovirus. A pre-existing history of diabetes mellitus or
247 autoimmune disease were included in subsequent regression models but were not significantly
248 associated with Long COVID outcomes and did not influence significance of other factors.

249 To further test the relationship between cross-neutralization of BA.5 pseudoviruses with the
250 development of Long COVID symptoms, we performed binary logistic regression including only the top
251 15% of neutralization ID50s in both the original SARS-CoV-2 and BA.5 variant based on results from a
252 sensitivity analysis to evaluate the influence of the samples with robust cross-neutralization of BA.5 as
253 shown in **Figure 3B**. Consistent with the above analyses, there were no significant associations
254 between the top neutralization responders to the original virus and PASC or PASC phenotype, whereas
255 presence of robust cross-neutralization to Omicron BA.5 was significantly associated with a higher odds
256 of any PASC symptom and neurocognitive and gastrointestinal PASC phenotypes. We repeated
257 regression analysis with ancestral wild-type and Omicron BA.5 in the same model and results were
258 similar with high cross-neutralization to BA.5 being significantly associated with any Long COVID
259 symptom and neurocognitive and gastrointestinal symptoms clusters (**Supplementary Figure 4B**).

260 **Decay of SARS-CoV-2-specific antibody neutralization over time by Long COVID phenotype.**

261 Finally, we assessed neutralizing antibody responses against the original infecting SARS-CoV-2 strain
262 by individual Long COVID phenotype (*i.e.* non mutually exclusive symptom cluster) compared to those
263 without any Long COVID symptoms or those with or without symptoms but not within the specific Long
264 COVID symptom cluster (**Figure 4A & B**, respectively). Overall, differences in levels across all time
265 points or changes over time were similar, with high interpatient variation in neutralization ID50s
266 observed. Nonetheless, we found that those with gastrointestinal and cardiopulmonary symptoms had
267 0.27 and 0.43 \log_{10} higher neutralization ID50 compared to those without any Long COVID symptom

268 across all data points over time ($P=0.04$ and <0.001 , respectively; **Figure 4A**). Decay in neutralization
269 ID50 was faster (*i.e.* more negative slope in mixed linear effects model) in participants with
270 cardiopulmonary and musculoskeletal symptoms compared to those without any symptoms ($P=0.01$
271 and 0.047 , respectively). Compared to those with or without persistent symptoms, but no symptoms in
272 the specified phenotype cluster, those with cardiopulmonary or musculoskeletal symptoms were overall
273 higher across all time points (both $P<0.001$), and those with musculoskeletal, cardiopulmonary and
274 neurocognitive symptoms declined more rapidly than those without those specific symptoms (all $P <$
275 0.05 ; **Figure 4B**).

276

277 **DISCUSSION**

278 In this longitudinal study of a well-characterized cohort of people recovering from COVID-19 during the
279 early waves of the pandemic prior to emergence of Delta and subsequent variants and availability of
280 vaccines, we identified several novel relationships between SARS-CoV-2 antibody neutralization and
281 the presence of Long COVID symptoms. First, we show that, although neutralizing antibody responses
282 to the original, infecting strain of SARS-CoV-2 were not associated with Long COVID in cross-sectional
283 analyses, cross-neutralization ID50 levels to the Omicron BA.5 variant approximately 4 months
284 following acute infection were independently and significantly associated with greater odds of Long
285 COVID in general and specifically with persistent gastrointestinal and neurological symptoms. These
286 data suggest that a broad antibody response to subsequent viral variants may predict emergence of
287 various LC symptoms. Supporting this finding, a recent preprint suggested that people with LC may
288 have an expanded antibody response against the prior OC43 endemic Coronavirus [23]. The
289 researchers also demonstrated more avid IgM responses and inflammatory OC43 S2-specific Fc-
290 receptor binding responses but weaker Fc-receptor binding to SARS-CoV-2 [23]. Whether or not the
291 association between breadth of response and LC is due to or related to processes such as autoreactive
292 antibody formation warrants further investigation.

293 Interestingly, we observed that a higher proportion of people infected early during the pandemic had
294 antibodies capable of neutralizing Omicron BA.5 compared with BA.1, to which very few participants
295 demonstrated any cross-neutralization response. The reason for this is not known, but several amino
296 acid mutations in the receptor binding domain (RBD) of SARS-CoV-2 Spike protein in the BA.1 strain
297 reverted to wild-type in the BA.5, such as G446S, Q493R and G496R [19, 30]. The BA.5 variant also
298 had reversion of amino acid mutations or insertions in non RBD areas of Spike to pre BA.1 variants
299 (e.g. L981F, ins214EPE, T95I) [19, 30]. In the sub-analysis of samples from 16 participants stratified by
300 the highest and lowest BA.5 neutralization titers, we also observed consistently higher cross-
301 neutralization with BA.2, BA.4.6 and BQ.1.1 sub variants. In contrast, lower neutralization ID50s to
302 XBB.1.5 pseudovirus were observed, similar to BA.1 neutralization. Whether or not there are any
303 clinical implications of increased cross-neutralization in those infected early in the pandemic with
304 subsequent Omicron variants is not known. It is also not clear if infection with Omicron strains leads to
305 increased or decreased risks of Long COVID, but it will be very difficult to identify variant-specific
306 effects in the current era of widespread and variable vaccination, reinfection, and antiviral treatment
307 uptake.

308 We also evaluated the longitudinal relationships between antibody neutralization responses, various
309 clinical factors, and Long COVID phenotypes. The mixed effects models allowed us to determine
310 differences between these variables across all data points over time (including multiple time points for
311 each individual) and changes (*i.e.* decay) over time. These analyses revealed relationships between
312 neutralization responses that were not observed in the cross-sectional analyses, such as significantly
313 higher SARS-CoV-2 neutralizing responses to the original infection SARS-CoV-2 across all time points
314 for those with gastrointestinal and cardiopulmonary Long COVID symptoms. Regardless of the overall
315 higher levels, a faster decay of neutralizing ID50 was observed for these phenotypic clusters, in
316 addition to those with musculoskeletal symptoms. Of note, neutralization titers decay more rapidly on a
317 whole than common epitope antibody responses which have been associated with various PASC

318 symptoms in longitudinal analyses [16, 17, 20], highlighting importance of temporal immune dynamics
319 in the study of this condition. Together, these and the cross-sectional data suggest that an overall
320 higher neutralization response that wanes more quickly, or ones that remain broad over time, are
321 associated with LC. While the causes of these dynamics are unknown, one possibility is that persistent
322 SARS-CoV-2 antigen presentation in tissues, which has been proposed as a potential mechanism of
323 Long COVID, may lead to overall higher antibody neutralization over time, and potentially to a broader
324 response to subsequent variants. While speculative, our findings suggest that relationships between
325 various immune responses and Long COVID are likely complex, and different approaches to data
326 analyses may yield different, but complementary information.

327 Strengths of this study include the use of highly characterized samples from the pre-vaccine and pre-
328 Omicron era, before reinfections became common. This allowed for a more straightforward analysis of
329 neutralization dynamics in the absence of these complex confounding factors. In addition, both those
330 with and without Long COVID were recruited and assessed in an identical manner, addressing potential
331 biases that might occur when comparison groups are derived from different cohorts as has been
332 common in studies of Long COVID. As in similar analyses where we have been able to evaluate
333 mechanisms according to distinct Long COVID phenotypes [9], we leveraged our high degree of
334 symptom characterization to analyze different case definitions of Long COVID. This approach is
335 informative, especially since the case definition remains controversial and it is possible that different
336 phenotypes are driven by different mechanisms. Limitations of the study include a lack of participants
337 infected with more recent variants, preventing us from extending our observations into more recent
338 waves of the pandemic. The cohort was a convenience sample, and although this allows for valid
339 inferences regarding Long COVID biology comparing people with and without the phenotype of interest
340 within the cohort, extrapolation to all individuals with prior COVID-19 must be done cautiously. The
341 neutralization assay used Spike protein pseudoviruses rather than intact, replication-competent virus,
342 but these pseudovirus assays have been shown to have comparable results in several studies [27, 29,

343 31-33]. Nonetheless, we believe that these results suggest at least one potential contributor to Long
344 COVID, although more work will be necessary to validate these observations in other cohorts, including
345 those derived from later waves of the pandemic in the setting of vaccination or reinfection.

346 FOOTNOTES

347 Funding sources This work was supported by the NIH/National Institute of Allergy and Infectious
348 Diseases 3R01AI141003-03S1 (TJH), K23A137522 (MJP), and K23AI162249 (AND).

349 Conflicts of Interest: MJP reports consulting fees for Gilead Sciences and AstraZeneca, outside the
350 submitted work. TJH receives grant support from Merck and Co. and has consulted for Roche and
351 Regeneron.

352 Acknowledgements: We are grateful to the study participants and their medical providers. We
353 acknowledge current and former LIINC clinical study team members Tamara Abualhsan, Andrea
354 Alvarez, Khamal Anglin, Urania Argueta, Mireya Arreguin, Kofi Asare, Melissa Buitrago, Monika
355 Deswal, Nicole DelCastillo, Emily Fehrman, Halle Grebe, Heather Hartig, Yanel Hernandez, Beatrice
356 Huang, Raushun Kirtikar, Monica Lopez, Michael Luna, Lynn Ngo, Enrique Martinez Ortiz, Antonio
357 Rodriguez, Justin Romero, Dylan Ryder, Ruth Diaz Sanchez, Matthew So, Celina Chang Song, Viva
358 Tai, Alex Tang, Cassandra Thanh, Fatima Ticas, Leonel Torres, Brandon Tran, Daisy Valdivieso, and
359 Deepshika Varma; and LIINC laboratory team members Joanna Donatelli, Jill Hakim, Nikita Iyer, Owen
360 Janson, Brian LaFranchi, Christopher Nixon, Isaac Thomas, and Keirstinne Turcios. We thank Jessica
361 Chen, Aidan Donovan, Carrie Forman, and Rania Ibrahim for assistance with data entry and
362 review. We thank the UCSF AIDS Specimen Bank for processing specimens and maintaining the LIINC
363 biospecimen repository. We are grateful to Elnaz Eilkhani and Monika Deswal for regulatory support.
364 We are also grateful for the contributions of LIINC leadership team members: Isabelle Rodriguez-
365 Barraquer, and Rachel Rutishauser.

366
367

Table 1. Participant demographics, comorbidities, and clinical presentation in participants with and without post-acute sequelae of SARS-CoV-2 infection

	All Participants	No Long COVID	Long COVID ^a
N	184	71	113
Female Sex	94 (51.1%)	28 (39.4%)	66 (58.4%)*
Age (median, IQR)	44 (34, 53)	43 (33, 53)	45 (36, 54)
COVID-19 Hospitalization	42 (22.8%)	14 (19.7%)	28 (24.8%)
Pre-Existing Medical Condition			
Diabetes Mellitus	20 (10.9%)	11 (15.5%)	9 (8.0%)
Autoimmune Disease	13 (7.1%)	1 (1.4%)	12 (10.6%)*
Race/Ethnicity			
Latinx	53 (28.8%)	14 (19.7%)	39 (34.5%)*
White	100 (54.3%)	40 (56.3%)	60 (53.1%)
Black/African American	4 (2.2%)	3 (4.2%)	1 (0.9%)
Asian	22 (12.0%)	13 (18.3%)	9 (8.0%)
American Indian/Native Alaskan	1 (0.5%)	0 (0%)	1 (0.9%)
Pacific Islander/Native Hawaiian	3 (1.6%)	0 (0%)	3 (4.2%)
Body Mass Index ^b	26.7 (23.4, 31.2)	26.0 (23.1, 28.8)	27.7 (23.6, 32.9)*

COVID-19 = coronavirus disease 2019; IQR = interquartile range

^a Long COVID as defined as any persistent symptom new since COVID-19 onset at least 3 months following acute infection.

^b n = 178 excluding missing values

* P < 0.05 by two-sided Fisher's exact test for categorical data or by two-sided Mann-Whitney U test for continuous data.

368


369

370

371 **Figures**

372

373



374

375

376

377

378

379

380

381

382

383

384


385

386

387



388

Figure 1. SARS-CoV-2 neutralization to the original infecting strain and cross-neutralization to subsequent viral variants. *Ex vivo* antibody neutralization of the original SARS-CoV-2 virus and subsequent variants approximately 1 month (A, N=69), 2 months (B, N=115), and 4 months (C, N=119) following acute infection for all participants. Subgroup analysis of cross-neutralization in an expanded Omicron sub variant panel (N=16) in a subset of participants that had samples across all timepoints with either high or negative neutralization to BA.5 (D). Most samples collected prior to SARS-CoV-2 vaccination and prior to the emergence of Delta and Omicron variants. Bars represent mean antibody (Ab) infectious dose 50% (ID₅₀) values and 95% confidence intervals (* P<0.05, ** P<0.01, ***P<0.001 by two-sided Freidman test adjusted for multiple comparisons).



389 **Figure 2. Longitudinal analysis of antibody neutralization by demographics, clinical factors and SARS-**
 390 **CoV-2 variant.** Mixed-linear regression model with four covariates (*i.e.* age, sex, hospitalization status, and prior
 391 diabetes history) for different variants: SARS-CoV-2, B.1.617.2, B.1.1.529 and BA.4/5. P-values denote if a
 392 significant difference was observed for change in antibody neutralization over time (Change over time), between
 393 subgroup (Phenotype, *e.g.*, no diabetes versus diabetes), and difference in change over time by subgroup
 394 (Change over time by phenotype, *e.g.* difference in slope of decline in antibody levels dependent on diabetes
 395 versus no diabetes). Shaded region represents 95% confidence intervals around the median line.

396



397

398

399

400

401

402

403

404

405


406

407

408

409

Figure 3. Association between SARS-CoV-2 neutralization, hospitalization during acute infection and demographic factors and the odds of experiencing Long COVID approximately four months following acute COVID-19. The top panel shows odds ratios (points) and 95% confidence intervals (bars) for each variable included in logistic regression models using continuous neutralization ID50 values for assays using the original and Omicron BA.5 pseudoviruses (**A**). The bottom panel shows odds ratios and 95% confidence intervals of developing PASC or specific PASC phenotypes for logistic regression models incorporating a binary variable indicating if a sample had a neutralization ID50 in the top 15% of the cohort to either original SARS-CoV02 or Omicron BA.5 pseudovirus (**B**). * P<0.05, ** P<0.01 from covariate adjusted logistic regression.



410
411
412
413
414
415
416
417
418
419

Figure 4. Differential decay of SARS-CoV-2-specific neutralizing antibody responses among Long COVID Symptom Phenotypes. Longitudinal decay of antibody responses compared between participants with Long COVID Symptom Phenotype (e.g. musculoskeletal, gastrointestinal, cardiopulmonary, neurocognitive) **a)** versus those without Long COVID (left panels) or **b)** versus those with other Long COVID Symptom Phenotypes (right panels). Each panel includes p-values for: the decay across all participants (“change over time”), differences in antibody neutralization for those with Long COVID phenotype across all timepoints (Symptom Phenotype), and differences in change over time with a given Long COVID phenotype (Change over time by phenotype). Shaded region represents 95% confidence intervals around the median line.

420 **REFERENCES**

421


- 422 1. Ayoubkhani, D., et al., Trajectory of long covid symptoms after covid-19 vaccination: community
423 based cohort study. *BMJ*, 2022. 377: p. e069676.
- 424 2. Seessle, J., et al., Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease
425 2019 (COVID-19): A Prospective Cohort Study. *Clin Infect Dis*, 2022. 74(7): p. 1191-1198.
- 426 3. Yang, C., et al., Omicron variants of SARS-CoV-2 and long COVID. *Front Immunol*, 2022. 13: p.
427 1061686.
- 428 4. Peluso, M.J., et al., Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality
429 of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for
430 Measurement. *Open Forum Infect Dis*, 2022. 9(2): p. ofab640.
- 431 5. Peluso, M.J., J. Donatelli, and T.J. Henrich, Long-term immunologic effects of SARS-CoV-2
432 infection: leveraging translational research methodology to address emerging questions. *Transl
433 Res*, 2021.
- 434 6. Peluso, M.J. and S.G. Deeks, Early clues regarding the pathogenesis of long-COVID. *Trends
435 Immunol*, 2022. 43(4): p. 268-270.
- 436 7. Mehandru, S. and M. Merad, Pathological sequelae of long-haul COVID. *Nat Immunol*, 2022.
437 23(2): p. 194-202.
- 438 8. Castanares-Zapatero, D., et al., Pathophysiology and mechanism of long COVID: a
439 comprehensive review. *Ann Med*, 2022. 54(1): p. 1473-1487.
- 440 9. Peluso, M.J., et al., Chronic viral coinfections differentially affect the likelihood of developing
441 long COVID. *J Clin Invest*, 2023. 133(3).
- 442 10. Su, Y., et al., Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell*, 2022.
443 185(5): p. 881-895 e20.
- 444 11. Gold, J.E., et al., Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr
445 Virus Reactivation. *Pathogens*, 2021. 10(6).
- 446 12. Swank, Z., et al., Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2
447 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. *Clin Infect Dis*, 2023.
448 76(3): p. e487-e490.
- 449 13. Natarajan, A., et al., Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA
450 suggest prolonged gastrointestinal infection. *Med (N Y)*, 2022. 3(6): p. 371-387 e9.
- 451 14. Peluso, M.J., et al., SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of
452 COVID-19. *Ann Neurol*, 2022. 91(6): p. 772-781.

- 453 15. Klein, J., et al., Distinguishing features of Long COVID identified through immune profiling.
454 medRxiv, 2022.
- 455 16. Fjelltveit, E.B., et al., Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild
456 Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control
457 Study. *Clin Infect Dis*, 2023. 76(3): p. e60-e70.
- 458 17. Kurahashi, Y., et al., Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants
459 After Infections. *Front Immunol*, 2022. 13: p. 773652.
- 460 18. Yin, K., et al., Long COVID manifests with T cell dysregulation, inflammation, and an
461 uncoordinated adaptive immune response to SARS-CoV-2. *bioRxiv*, 2023.
- 462 19. Gruell, H., et al., Antibody-mediated neutralization of SARS-CoV-2. *Immunity*, 2022. 55(6): p.
463 925-944.
- 464 20. Peluso, M.J., et al., Long-term SARS-CoV-2-specific immune and inflammatory responses in
465 individuals recovering from COVID-19 with and without post-acute symptoms. *Cell Rep*, 2021.
466 36(6): p. 109518.
- 467 21. Peluso, M.J., et al., SARS-CoV-2 antibody magnitude and detectability are driven by disease
468 severity, timing, and assay. *Sci Adv*, 2021. 7(31).
- 469 22. Garcia-Abellan, J., et al., Antibody Response to SARS-CoV-2 is Associated with Long-term
470 Clinical Outcome in Patients with COVID-19: a Longitudinal Study. *J Clin Immunol*, 2021. 41(7):
471 p. 1490-1501.
- 472 23. Herman, J.D., et al., Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19.
473 medRxiv, 2022.
- 474 24. Sullivan, D.J., et al., Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in
475 different vaccinated and unvaccinated convalescent plasma sources. *Nat Commun*, 2022.
476 13(1): p. 6478.
- 477 25. Linderman, S.L., et al., Neutralizing antibody responses in patients hospitalized with SARS-
478 CoV-2 Delta or Omicron infection. *J Clin Invest*, 2022. 132(23).
- 479 26. Odak, I., et al., Longitudinal Tracking of Immune Responses in COVID-19 Convalescents
480 Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other
481 SARS-CoV-2 Variants of Concern. *Front Immunol*, 2022. 13: p. 863039.
- 482 27. Schuh, A.J., et al., SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody
483 Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic
484 Infection. *Microbiol Spectr*, 2022. 10(4): p. e0124722.
- 485 28. Fong, Y., et al., Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy
486 clinical trial. *Nat Commun*, 2023. 14(1): p. 331.

- 487 29. Huang, Y., et al., Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays
488 for COVID-19 vaccine evaluation. *Sci Rep*, 2021. 11(1): p. 23921.
- 489 30. Kurhade, C., et al., Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1
490 by parental mRNA vaccine or a BA.5 bivalent booster. *Nat Med*, 2023. 29(2): p. 344-347.
- 491 31. Mi, D., J. Hu, and Z. Qian, A Lentiviral Pseudotype System to Characterize SARS-CoV-2
492 Glycoprotein. *Methods Mol Biol*, 2023. 2610: p. 187-199.
- 493 32. Hyseni, I., et al., Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation
494 between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation
495 Assays. *Viruses*, 2020. 12(9).
- 496 33. Liu, K.T., et al., Overview of Neutralization Assays and International Standard for Detecting
497 SARS-CoV-2 Neutralizing Antibody. *Viruses*, 2022. 14(7).
- 498
- 499

500 SUPPLEMENTARY MATERIALS

501



502

503

503 **Supplementary Figure 1. Correlation Matrix of Neutralization ID50s For SARS-CoV-2 variants**
504 **tested.** Data across all time points are shown in the matrices. R and P values from non-parametric
505 Spearman rank correlation analyses.

506

507


508

509

510


511

512
513




514
515
516
517
518
519
520
521
522
523
524
525
526

Supplementary Figure 2. Longitudinal analysis of antibody neutralization by clinical factors and SARS-CoV-2 variant. Mixed-linear regression model with two covariates (body mass index and autoimmune disease history) for different variants: SARS-CoV-2, B.1.617.2, B.1.1.529 and BA.4/5. P-values denote if a significant difference was observed for change in antibody neutralization over time (Change over time), between subgroup (Phenotype, e.g., BMI \geq 30), and difference in change over time by subgroup (Change over time by phenotype). Shaded region represents 95% confidence intervals around the median line.



527
528
529
530
531
532
533
534
535
536
537
538
539

Supplementary Figure 3. Association between SARS-CoV-2 neutralization, hospitalization during acute infection and demographic factors and the odds of experiencing fatigue or cardiopulmonary symptoms approximately four months following acute COVID-19. The top panel shows odds ratios (points) and 95% confidence intervals (bars) for each variable included in logistic regression models using continuous neutralization ID50 values for assays using the original and Omicron BA.5 pseudoviruses (A). The bottom panel shows odds ratios and 95% confidence intervals of developing PASC or specific PASC phenotypes for logistic regression models incorporating a binary variable indicating if a sample had a neutralization ID50 in the top 15% of the cohort to either original SARS-CoV2 or Omicron BA.5 pseudoviruses (B). *P<0.05, **P<0.01, ***P<0.001 from covariate adjusted logistic regression.



540
541
542
543
544
545
546
547
548
549
550
551
552

Supplementary Figure 4. Association between SARS-CoV-2 neutralization, hospitalization during acute infection and demographic factors and the odds of experiencing fatigue or cardiopulmonary symptoms approximately four months following acute COVID-19. The top panel shows odds ratios (points) and 95% confidence intervals (bars) for each variable included in logistic regression using continuous neutralization ID50 values for assays using the original and Omicron BA.5 pseudoviruses in the same model (A). The bottom panel shows odds ratios and 95% confidence intervals of developing PASC or specific PASC phenotypes for logistic regression incorporating a binary variable indicating if a sample had a neutralization ID50 in the top 15% of the cohort to the original SARS-CoV2 and Omicron BA.5 pseudoviruses (B). *P<0.05, **P<0.01, ***P<0.001 from covariate adjusted logistic regression.